Avi Berger

Former Chief Executive Officer & Senior Partner at PricewaterhouseCoopers (Israel)

Avi Berger

Avi Berger

Former Chief Executive Officer & Senior Partner at PricewaterhouseCoopers (Israel)

Biography

Avraham (Avi) Berger is the owner and CEO of AB6C Ltd., a private consulting company, as of 2015. From November 2013 until May 2015, Mr. Berger served as the Director General of the Israeli Ministry of Communication. During the years 2012 to 2013, Mr. Berger served as VP Marketing and business developing of Ness-TSG. From 2007 to 2012 Mr. Berger served as the VP technology & CTO of Partner Communication Ltd., and during 2007 Mr. Berger served as VP business development of Tadiran Communication Ltd. From 1985 to 2006, he served in the Israel Defense Forces C4I and Cyber Branch, and Signal Corps, in a number of telecommunication and command control development and project management positions, retiring as a full colonel. Mr. Berger holds a B.Sc. in Electrical Engineering from Tel Aviv University, and M.Sc.in Electrical Engineering from UCLA.

Overview
Career Highlights

PricewaterhouseCoopers (Israel)

RelSci Relationships

361

Number of Boards

3

Birthday

1952

Age

67

Relationships
RelSci Relationships are individuals Avi Berger likely has professional access to. A relationship does not necessarily indicate a personal connection.

President at Weizmann Institute of Science

Relationship likelihood: Strong

Vice President at Weizmann Institute of Science

Relationship likelihood: Strong

Former Partner at PricewaterhouseCoopers (Israel)

Relationship likelihood: Strong

Dean, Faculty of Chemistry at Weizmann Institute of Science

Relationship likelihood: Strong

Dean, Faculty of Mathematics & Computer Science at Weizmann Institute of Science

Relationship likelihood: Strong

Dean, Education at Weizmann Institute of Science

Relationship likelihood: Strong

Dean, Feinberg Graduate School at Weizmann Institute of Science

Relationship likelihood: Strong

Dean, Faculty of Biochemistry at Weizmann Institute of Science

Relationship likelihood: Strong

Dean, Faculty of Biology at Weizmann Institute of Science

Relationship likelihood: Strong

Dean, Faculty of Physics at Weizmann Institute of Science

Relationship likelihood: Strong

Paths to Avi Berger
Potential Connections via
Relationship Science
You
Avi Berger
Former Chief Executive Officer & Senior Partner at PricewaterhouseCoopers (Israel)
Education

Tel Aviv University (TAU) (Hebrew: ?????????? ???????? Universitat Tel Aviv) is a public university located in Ramat Aviv, Tel Aviv, Israel. With nearly 30,000 students, TAU is Israel's largest university. Located in Israel's cultural, financial and industrial core, Tel Aviv University is a major center of teaching and research, comprising 9 faculties, 27 schools, 98 departments and 128 research institutes and centers. Its origins go back to 1956, when three research institutes – the Tel Aviv School of Law and Economics, the Institute of Natural Sciences, and the Institute of Jewish Studies – joined together to form the University of Tel Aviv. Initially operated by the Tel Aviv municipality, the university was granted autonomy in 1963. The university also maintains academic supervision over the Center for Technological Design in Holon, the New Academic College of Tel Aviv-Yaffo, and the Afeka College of Engineering in Tel Aviv. The Wise Observatory is located in Mitzpe Ramon.

Career History
Chief Executive Officer & Senior Partner
1976 - 2014

PricewaterhouseCoopers (Israel), a subsidiary of PricewaterhouseCoopers International Ltd., is a company headquartered in Tel Aviv, Israel, that provides legal services.

Boards & Committees
Member, Board of Directors
2016 - Current

Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology. Kamada´s product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The Company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility. Kamada’s flagship product is Glassia®; an FDA approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein, for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use and stabilizer free augmentation treatment .Kamada has a strategic agreement with Baxter for US marketing, distribution and licensing of Glassia®. Kamada’s second generation AAT product is an inhaled (IH) version. This product is already in advanced stages of clinical development for the treatment of AAT Deficiency. Other potential indications for AAT (IV or IH) include bronchiectasis, cystic fibrosis, COPD as well as type-1 diabetes for which the Company started a clinical trial. Sided to its capabilities to manufacture specialty proteins, Kamada has developed a platform technology for the production of specific immunoglobulins (IgGs). Kamada´s unique know-how and capabilities enable it to seek for new business opportunities and offer a wide scope of pharma-oriented services, including: R&D of new biopharmaceuticals, large scale production of high quality biopharmaceuticals, formulation and aseptic filling, registration and marketing. Over the years Kamada has established its presence in the pharma industry worldwide. Kamada’s mission is to develop, manufacture and provide high quality, specialty pharmaceuticals to patients, in order to support better quality of life and save lives. Founded in 1990, Kamada successfully completed an Initial Public Offering in 2005.The company is traded at the Tel Aviv Stock Exchange (KMDA). Kamada's headquarters is located in the Weizmann Science Park in Nes Ziona, Israel

Member, Board of Directors
Current

Ceragon Networks Ltd. engages in the provision of wireless backhaul solutions. Its products include radio units, management systems, small cell hauling, packet and hybrid microwave, and long haul solutions. The company renders transmission capacity to mobile and fixed-line carriers, and private network operators. Ceragon Networks was founded on July 23, 1996 and is headquartered in Tel Aviv, Israel.

Director
Current

The Weizmann Institute of Science is one of the world’s leading multidisciplinary research institutions. Hundreds of scientists, laboratory technicians and research students working on its lushly landscaped campus embark daily on fascinating journeys into the unknown, seeking to improve our understanding of nature and our place within it. Lettuce fieldGuiding these scientists is the spirit of inquiry so characteristic of the human race. It is this spirit that propelled humans upward along the evolutionary ladder, helping them reach their utmost heights. It prompted humankind to pursue agriculture, learn to build lodgings, invent writing, harness electricity to power emerging technologies, observe distant galaxies, design drugs to combat various diseases, develop new materials and decipher the genetic code embedded in all the plants and animals on Earth. The quest to maintain this increasing momentum compels Weizmann Institute scientists to seek out places that have not yet been reached by the human mind. What awaits us in these places? No one has the answer to this question. But one thing is certain – the journey fired by curiosity will lead onward to a better future. Groundbreaking medical and technological applications that have emerged from basic research conducted by Weizmann Institute scientists include: Amniocentesis, a prenatal diagnostic test for the fetus neonatal Sophisticated laser systems for high-precision diamond cutting A method for growing hybrid seeds that prevents the transmission of disease from one generation to the next and helps protect edible plants from pests Affinity chromatography, a key tool for purifying biological materials in the biotechnology industry Living polymerization, one of the most fundamental techniques of the modern polymer industry For solving the structure of the ribosome, the cell’s protein factory, and revealing its means of action, the Institute’s Prof. Ada Yonath was awarded a Nobel Prize in Chemistry. Her research should speed the development of antibiotic drugs that are more efficient, especially against antibiotic-resistant strains

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Avi Berger. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Avi Berger's profile does not indicate a business or promotional relationship of any kind between RelSci and Avi Berger.